Chloramphenicol

證據等級: L5

預測適應症: 10 個

Chloramphenicol: From Bacterial Infections to Conjunctivitis

Disclaimer: This report is for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application. This content is generated by the TxGNN model and has not been reviewed by SAHPRA.

One-Sentence Summary

Chloramphenicol is a broad-spectrum bacteriostatic antibiotic historically used for serious bacterial infections including typhoid fever, bacterial meningitis, and Rickettsia infections. The TxGNN model predicts it may be effective for Conjunctivitis with a prediction score of 99.66%. Critically, this represents a data collection gap rather than a true evidence gap — chloramphenicol ophthalmic preparations are already approved as first-line therapy for bacterial conjunctivitis in the United Kingdom (available OTC) and Australia, supported by multiple RCTs and extensive post-marketing surveillance data; the automated search simply did not capture this body of evidence.

Quick Overview

Item	Content
Original Indication	Serious bacterial infections (typhoid fever, bacterial meningitis, Rickettsia infections)
Predicted New Indication	Conjunctivitis
TxGNN Prediction Score	99.66%
Evidence Level	L3
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, chloramphenicol is a broad-spectrum bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby blocking peptide bond formation. This mechanism is active against a wide range of Gram-positive cocci, Gram-negative rods, and obligate intracellular pathogens such as Rickettsia and Chlamydia species.

Bacterial conjunctivitis is most commonly caused by organisms with well-documented susceptibility to chloramphenicol: Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. A topical ophthalmic formulation (0.5% eye drops or 1% eye ointment) delivers effective local concentrations directly at the conjunctival surface while substantially circumventing systemic absorption — thereby mitigating the primary safety concern of bone marrow suppression associated with systemic chloramphenicol use.

The TxGNN prediction aligns precisely with established global clinical practice. Chloramphenicol ophthalmic preparations hold full regulatory approval for bacterial conjunctivitis in the United Kingdom (Brolene®, Optrex® brands; partially OTC) and Australia. This is not a speculative indication — it is already the clinical standard in multiple high-income regulatory jurisdictions. The absence of results in the automated evidence query reflects a search methodology gap, not a lack of supporting evidence. Manual retrieval of Cochrane systematic reviews and published RCTs on antibiotic eye drops for acute bacterial conjunctivitis is expected to yield substantial L1–L2 evidence.

Clinical Trial Evidence

⚠️ Data Collection Gap Notice: The automated search returned 0 results for chloramphenicol + conjunctivitis on ClinicalTrials.gov and ICTRP. This is a known limitation of keyword-based searches for well-established ophthalmic indications. Chloramphenicol eye drops have been in routine clinical use for bacterial conjunctivitis since the 1950s and are approved OTC in the UK; relevant RCT evidence predates systematic trial registration and may not appear in ClinicalTrials.gov. Manual retrieval (e.g., Cochrane CENTRAL, EMBASE, SANCTR, Pan African Clinical Trials Registry [PACTR]) is strongly recommended.

Currently no related clinical trials registered in the automated query.

Literature Evidence

⚠️ Data Collection Gap Notice: The automated PubMed search returned 0 publications for chloramphenicol + conjunctivitis. Relevant evidence includes the Cochrane systematic review by Sheikh & Hurwitz (Antibiotics versus placebo for acute bacterial conjunctivitis) and multiple published RCTs on topical antibiotic eye drops. These were not captured in the current automated query and must be retrieved manually to complete the evidence base.

Currently no related literature captured in automated query.

South Africa Market Information

Chloramphenicol currently has no active SAHPRA product registrations and is not marketed in South Africa.

Registration Number	Product Name	Dosage Form	Approved Indication
—	No registered products	—	—

Regulatory Pathway Note: Given chloramphenicol’s established ophthalmic safety and efficacy profile (UK/Australia OTC approval for bacterial conjunctivitis), the following regulatory pathways warrant consideration:

New product registration with SAHPRA for a 0.5% ophthalmic solution and/or 1% ophthalmic ointment

Section 21 authorisation for interim access pending full registration

Essential Medicines List (EML) evaluation — bacterial conjunctivitis is a high-burden condition in primary healthcare settings across South Africa; EML inclusion would support equitable access at the district hospital and primary healthcare clinic level

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for complete safety information once registration is obtained. Report adverse drug reactions to SAHPRA via the MedSafety online reporting portal.

Note: Formal SAHPRA PI data is currently unavailable (Data Gap DG001 — severity: Blocking). The following is based on internationally published safety data and should not substitute for a regulatory-approved South African PI.

Key Known Safety Considerations (topical ophthalmic use):

Bone marrow suppression: The principal safety concern with chloramphenicol is myelosuppression — both dose-dependent reversible effects and rare idiosyncratic aplastic anaemia (estimated incidence 1:25,000–1:40,000 with systemic use). Topical ophthalmic formulations have substantially lower systemic absorption and have been assessed as having an acceptable risk profile for OTC topical use by the UK MHRA and the Australian TGA. Nonetheless, prolonged or repeated courses should be avoided.
Hypersensitivity: Local hypersensitivity reactions (contact dermatitis, ocular irritation) may occur.
Neonates and premature infants: Systemic chloramphenicol is contraindicated in neonates due to “grey baby syndrome” (cardiovascular collapse from impaired glucuronidation). Ophthalmic use in neonates should be approached with caution pending specific South African PI guidance.
Duration of use: Courses should generally not exceed 5 days for acute bacterial conjunctivitis; clinical re-evaluation is required if symptoms do not resolve.
No drug interaction data was identified in the automated query for this drug–disease combination.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction for chloramphenicol in bacterial conjunctivitis is strongly validated by established international regulatory approvals (UK, Australia) and is mechanistically sound — the drug’s broad-spectrum bacteriostatic activity directly targets the causative pathogens of bacterial conjunctivitis, and the topical ophthalmic route effectively addresses the systemic safety concern. The high prediction score (99.66%) reflects genuine clinical and mechanistic validity. The primary barriers to deployment in South Africa are regulatory (no SAHPRA registration) and safety documentation (no South African PI), not clinical evidence.

To proceed, the following is needed:

[Priority 1 — Blocking] Obtain or commission SAHPRA-approved Professional Information (PI) for chloramphenicol ophthalmic preparations; resolve Data Gap DG001 before S1 safety evaluation can proceed
[Priority 2 — High] Conduct manual literature retrieval: Cochrane systematic reviews (Sheikh & Hurwitz), published RCTs on topical chloramphenicol for bacterial conjunctivitis, and UK MHRA/Australian TGA product assessment reports to establish formal L1–L2 evidence documentation
[Priority 3] Initiate SAHPRA product registration application for chloramphenicol 0.5% ophthalmic solution and 1% ophthalmic ointment; assess feasibility of Section 21 authorisation as an interim measure
[Priority 4] Evaluate suitability for inclusion on South Africa’s Essential Medicines List (EML) for primary healthcare, given the public health burden of bacterial conjunctivitis and the low cost of the formulation
[Priority 5] Retrieve DrugBank MOA data to complete mechanistic documentation (Data Gap DG002)
[Priority 6] Register any planned South African clinical evaluation studies with SANCTR (South African National Clinical Trials Register) and consider PACTR (Pan African Clinical Trials Registry) registration for regional visibility
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.